AF
Therapeutic Areas
Perceive Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lead Dry AMD Program | Dry Age-Related Macular Degeneration | Preclinical |
| Neuroprotection Program | Retinal Neurodegeneration | Preclinical |
Leadership Team at Perceive Biotherapeutics
KA
K. Angela Macfarlane, JD
CEO
AR
Anne Rubin, MBA
President
LA
Larry A. Wheeler, PhD
Chief Technical Officer
ED
Eugene De Juan, Jr., MD
Chief Strategy Officer
GS
Gregory S. Hageman, PhD
Chief Science Officer
DW
Derek Welsbie, MD, PhD
SAB Co-Chair
DZ
Don Zack, MD, PhD
SAB Co-Chair